Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2011; 6(4): e17919.
Published online Apr 21, 2011. doi:  10.1371/journal.pone.0017919
PMCID: PMC3080876
The Seroprevalence of Pandemic Influenza H1N1 (2009) Virus in China
Cuiling Xu,# 1 Tian Bai,# 1 A. Danielle Iuliano, 3 Min Wang, 1 Lei Yang, 1 Leying Wen, 1 Yuhong Zeng, 1 Xiaodan Li, 1 Tao Chen, 1 Wei Wang, 1 Ying Hu, 1 Limei Yang, 1 Zi Li, 1 Shumei Zou, 1 Dexin Li, 1 Shiwen Wang, 1 Zijian Feng, 2 Yanping Zhang, 1 Hongjie Yu, 2 Weizhong Yang, 2 Yu Wang, 2 Marc-Alain Widdowson, 3 and Yuelong Shu 1 *
1State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Infectious Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
2Chinese Center for Disease Control and Prevention, Beijing, China
3Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Eng Eong Ooi, Editor
Duke-National University of Singapore Graduate Medical School, Singapore
#Contributed equally.
* E-mail: yshu/at/
Conceived and designed the experiments: DL SW ZF Y. Zhang WY YW HY YS. Performed the experiments: TB MW LW Y. Zeng XL WW YH ZL SZ. Analyzed the data: CX. Contributed reagents/materials/analysis tools: CX. Wrote the paper: CX TB ADI. Full access to data and responsibility for the integrity of the data and the accuracy of the data analysis: YS. Critical revision of the manuscript for important intellectual content: CX ADI M-AW YS. Administrative, technical, or material support: TB MW Lei Yang LW Y. Zeng XL WW YH LZ SZ TC Limei Yang. Study supervision: SW ZF Y. Zhang.
Received August 4, 2010; Accepted February 17, 2011.
Mainland China experienced pandemic influenza H1N1 (2009) virus (pH1N1) with peak activity during November-December 2009. To understand the geographic extent, risk factors, and attack rate of pH1N1 infection in China we conducted a nationwide serological survey to determine the prevalence of antibodies to pH1N1.
Methodology/Principal Findings
Stored serum samples (n = 2,379) collected during 2006-2008 were used to estimate baseline serum reactogenicity to pH1N1. In January 2010, we used a multistage-stratified random sampling method to select 50,111 subjects who met eligibility criteria and collected serum samples and administered a standardized questionnaire. Antibody response to pH1N1 was measured using haemagglutination inhibition (HI) assay and the weighted seroprevalence was calculated using the Taylor series linearization method. Multivariable logistic regression analyses were used to examine risk factors for pH1N1 seropositivity. Baseline seroprevalence of pH1N1 antibody (HI titer ≥40) was 1.2%. The weighted seroprevalence of pH1N1 among the Chinese population was 21.5%(vaccinated: 62.0%; unvaccinated: 17.1%). Among unvaccinated participants, those aged 6-15 years (32.9%) and 16-24 years (30.3%) had higher seroprevalence compared with participants aged 25–59 years (10.7%) and ≥60 years (9.9%, P<0.0001). Children in kindergarten and students had higher odds of seropositivity than children in family care (OR: 1.36 and 2.05, respectively). We estimated that 207.7 million individuals (15.9%) experienced pH1N1 infection in China.
The Chinese population had low pre-existing immunity to pH1N1 and experienced a relatively high attack rate in 2009 of this virus. We recommend routine control measures such as vaccination to reduce transmission and spread of seasonal and pandemic influenza viruses.
On June 11, 2009, the World Health Organization (WHO) declared the first influenza pandemic of the21st century caused by a novel swine-origin influenza A H1N1 virus [1], which contains gene segments derived from classical swine H1N1 virus, human seasonal influenza H3N2 virus, avian influenza H1N1 virus and Eurasian swine H1N1 influenza virus [2].
Studies on the extent of infection with pH1N1 are essential for pandemic severity assessment and for the development of response and vaccination strategies. Modeling methods have been used to estimate the incidence of infection during the pandemic period, using clinical surveillance data in which only patients with influenza-like illness who seek care are captured, while those who do not seek care or have asymptomatic infections are excluded [3][5]. These estimates provide useful and timely information, but may lead to an underestimation of the actual number of infections. Therefore, serological studies have been recommended to more accurately estimate the attack rate and the extent of infection of 2009 pandemic influenza A H1N1 (pH1N1) virus infection [6]. Such serological studies have previously been conducted using convenience serum samples [7][13]. Miller, et al. estimated that approximately one in every three children in the United Kingdom (UK) had serological evidence of pH1N1 infection which was nearly ten times higher than the estimated incidence of pH1N1 from clinical surveillance [7]. Chen, et al. estimated that 13% of participants from a community cohort of adults in Singapore had serological evidence of pH1N1 infection following the June to September 2009 wave of pH1N1 [8].
On May 11, 2009, the first imported human pH1N1 case was detected in mainland China. Activity for pH1N1 remained low until the end of August, increased sharply in September, and peaked in late November. The purpose of this study was to estimate the baseline cross reactive antibody response to pH1N1 virus prior to introduction of the virus in mainland China using a convenience sample of serum collected during 2006–2008, to estimate the attack rate or seroprevalence of pH1N1 infection after the first wave of pH1N1 infection in January 2010 using a serological study (Figure S1), and to examine factors associated with serological response to pH1N1 infection. We conducted a multi-stage random-sampling serological study to determine the seroprevalence of pH1N1 in mainland China representative of different areas and ages, to understand the geographic extent of infection and to assess risk factors of pH1N1 infection in China. Combining the findings from these two studies, we were able to also estimate the attack rate of pH1N1 infection after the first wave of the pandemic in mainland China.
Baseline cross reactive antibody response to pandemic influenza H1N1 (2009) virus
The baseline cross reactive antibody response to pH1N1 infection (HI titer of ≥40) by age group among the convenience sample of 2,379 individuals is shown in Table 1. The overall baseline cross reactive antibody response to pH1N1 infection among the population was 1.2% (95% confidence interval [95% CI]: 0.7–1.6%). Examining the data by age group showed that individuals aged 16–24 had the highest baseline cross reactive antibody response to pH1N1 infection (3.3%) in comparison with individuals in other age categories (0–5 years: 0%, 6–15 years: 1.1%, 25–59 years: 0.6%, ≥60 years: 2.0%).
Table 1
Table 1
Proportion of baseline sera reactive to pandemic influenza H1N1 (2009) virus in each age group, 2006–2008.
Characteristics of study population of the cross-sectional seroprevalence study
In January 2010 we enrolled 50,458 subjects in the cross-sectional study. Of those, 50,403 blood samples were collected and 50,350 participants completed both the questionnaire and blood sample collection. Of these, 239 subjects were excluded because of missing demographic data (n = 161) or having insufficient serum sample (n = 78), leaving data from 50,111 (99.5%) subjects for analysis, Demographic characteristics of the entire sample are shown in Table 2. There were no statistically significant differences in the distribution of the data by age group, gender, region, and community setting (capital city, urban area, or rural) between the study subjects and the true Chinese population. There were 7,799 (15.6%) subjects who reported receiving the pH1N1 vaccine compared with 42,300 (84.4%) who reported not receiving the pH1N1 vaccine, and 12 (0.02%) subjects reported unknown vaccination history. Using sampling weight constructed based on the multi-stage random sampling design to adjust for oversampling of certain age groups and community settings, the weighted proportion of the Chinese population estimated to have received pH1N1 vaccine was 9.7%. Among unvaccinated participants, 39.4% were children in kindergarten or students, 7.3% were children in family care, 4.6% were teachers, doctors or nurses while nearly half (48.7%) reported other occupation (Table 2).
Table 2
Table 2
Characteristics of study population in the cross-sectional survey, January 2010.
Weighted prevalence of pandemic influenza H1N1 (2009) virus
Among 50,111 study subjects, 14,776 (29.5%) were antibody positive for the pH1N1 virus. Since we employed a multi-stage sampling method we adjusted for age and other factors to calculate a weighted pH1N1 seroprevalence of 21.5% (95% CI: 20.5–22.5) in the whole Chinese population. The weighted prevalence of pH1N1 antibody response for the subjects who reported receiving vaccine was significantly higher 62.0% (95% CI: 58.8–65.3) than subjects who did not report receiving the vaccine 17.1% (95% CI: 16.1–18.0) (p<0.0001).
Among the unvaccinated study population, we found that individuals aged 6–15 years (32.9%) and 16–24 years (30.3%) had the highest weighted prevalence, individuals aged 25–59 years (10.7%) and ≥60 years (9.9%) had the lowest (Table 3). When examining the weighted seroprevalence among the unvaccinated study population, we found that students had the highest weighted seroprevalence (34.9%), followed by children in kindergarten (26.2%), and participants with other occupations (11.1%). Further, among unvaccinated subjects, weighted prevalence of pH1N1 in eastern provinces (15.2%) was statistically significantly lower than the prevalence in both central (18.6%) and western provinces (19.3%). Among the unvaccinated, the weighted prevalence of pH1N1 infection in other urban areas (19.6%) was statistically significantly higher than the weighted prevalence in rural areas (15.8%), and higher than that in capital cities (17.1%) though the difference between capital cities and other urban areas was not.
Table 3
Table 3
Weighted seroprevalence of 2009 pandemic H1N1 virus antibodies by demographic characteristics among subjects who reported not receiving pH1N1 vaccine (N = 42,300).
To control for possible interactions between factors, multivariable logistic regression was used to estimate the odds ratio (OR) and 95% Confidence Interval (95% CI) for factors associated with pH1N1 antibody response among subjects who reported not receiving the pH1N1 vaccine (Table 4). The adjusted odds of seropositivity to pH1N1 infection for the eastern region (OR: 0.80, 95% CI: 0.68–0.93) were statistically significantly lower than the odds of infection in the western region. There was no statistically significant difference in the odds of infection between the central region (OR: 1.02, 95% CI: 0.89–1.18) and the western region. The odds of pH1N1 infection in the rural areas was statistically significantly lower (OR: 0.79, 95% CI: 0.69–0.90) compared with the odds of infection in other urban areas. The odds of pH1N1 infection in capital city areas (OR: 0. 97, 95% CI: 0.83–1.12) were lower than other urban areas, but were not statistically significantly different from those in other urban areas. Children in kindergarten (OR: 1.36, 95% CI: 1.05–1.76) and students (OR: 2. 04, 95% CI: 1.64–2.54) had significantly higher odds of pH1N1 seropositivity than children who were in family care. In contrast, subjects with other occupation (OR: 0.46, 95% CI: 0.37–0.58) had lower odds of pH1N1 antibody response compared with children in family care. The odds of seropositivity were not statistically different by gender (Table 4).
Table 4
Table 4
Adjusted odds ratios and 95% Confidence Intervals of pH1N1 infection among subjects who reported not receiving pH1N1 vaccine (N = 42,300).
Attack rate of pandemic influenza H1N1 (2009) virus in the Chinese Population
We estimated the attack rate of infection of pH1N1 from May 2009 to January 2010 to be 15.9% (95% CI: 15.3–16.5%) by subtracting the baseline cross reactive antibody response to pH1N1 infection (1.2%) from the estimated seroprevalence of pH1N1 infection from our study (17.1%). The attack rates by age group were 24.7% (0–5 y), 31.8% (6–15 y), 27% (16–24 y), 10.1% (25–59 y) and 8% (60+y). The estimated number of pH1N1 infections was calculated by multiplying the estimated seroincidence of infection (15.9%) by the total population on mainland China (1,306.3 million) to give a total number of pH1N1 cases of 207.7 million.
We aimed to estimate the adjusted seroprevalence of antibodies to pH1N1 among Chinese adults and children, to estimate the total number of persons infected in China, and to understand risk factors for infection among this population. We found that the seropositivity to pH1N1 was 17.1% after excluding individuals who reported receiving the pH1N1 vaccine, but that the baseline pre-pandemic seropositivity percent was 1.2%, giving an attack rate of pH1N1 in the first pandemic wave of 15.9% in the period May 2009 to January 2010. Further, our study showed that the seroprevalence of pH1N1 infection was higher in the central and western regions compared with the eastern region, higher in urban compared to rural areas and higher in school-aged children (6–15 years).
To our knowledge, this is the first time a multi-stage random-sampling serological study to investigate the seroprevalence of pH1N1 in China has been conducted. We used a serological survey to examine the seroprevalence of pH1N1 because of limitations of the clinical surveillance system in capturing true prevalence of pH1N1 infection. The clinical surveillance systematically captures individuals who seek medical care at hospitals that conduct the surveillance. However, it has been reported that many 2009 pandemic influenza H1N1 cases were mild [14][16] and many of those with infection may not have sought medical care and would not have been tested for infection. Additionally, studies have suggested that asymptomatic pH1N1 infection may be common [14]. Our serosurvey results suggest that approximately 207.7 million people in mainland China were infected with pH1N1 from May 2009 to January 2010. As of 31 January 2010, 126,449 clinical pH1N1 cases confirmed through respiratory specimens were reported in mainland China [17], implying that each such confirmed case of pH1N1 represented a possible 1,630 infections.
Our study had several limitations. The haemagglutination-inhibition (HI) assay may not be the most sensitive assay to detect low levels of pH1N1 compared to for example microneutralization, and we may have underestimated seropositivity both in the baseline and the serological survey samples. Also though we recorded a high percentage of seropositive persons who did not report symptoms, this may be due to potential recall bias and we were unable to confirm the presence or absence of respiratory symptoms. Lastly, we were not able to confirm receipt or not of pH1N1 vaccine, and it is possible that people reported receipt of different vaccines as pH1N1 vaccine.
Our study showed school-aged population and young adults had the highest attack rates of pH1N1, which is consistent with studies from the UK and Hong Kong [7], [13]. The attack rate of pH1N1(31.8%) among individuals aged 6–15 yrs was lower compared with individuals aged 5–14 yrs (42%) in the UK study and the attack rate among individuals in Hong Kong aged 5–14 years was 43.4%) [7], [13].
Our findings also indicated that 1.2% of the population had baseline cross reactive antibody response to pH1N1 and only 2.0% of adults aged ≥60 years had an antibody response. Unlike other countries such as the United States, the United Kingdom, Germany, and Finland [7], [9], [18], [19], older adults in China had a lower baseline antibody response to the pH1N1 virus. These findings were similar to findings from a serological study conducted in the Guangxi province of China and other studies in Japan and Singapore [8], [20][23]. The lower antibody response among older adults in our study could indicate little or no cross reactivity with previous swine-origin influenza A viruses and is consistent with data from Singapore, but not with recent data from Taiwan [8], [11]. The finding that individuals living in Eastern regions had lower seroprevalence of pH1N1 infection compared with individuals living in both Central and Western regions is similar to findings from the Chinese National Surveillance System during peak influenza periods, the hospital based surveillance system that monitors trends of influenza-like illness. One possible reason why the Eastern region experienced lower seroprevalence of infection although this region is more densely populated and includes most of the major cities in the country is that the eastern region had higher economic level, higher education level and more funding for health care than both the central and western regions (expenditure for health care per capita in 2009: eastern, RMB 929.81; central, RMB 753.09; western, RMB 739.64) [25]. Additionally, our results showed that the seroprevalence of pH1N1 infection was higher in urban areas compared to rural areas. We speculate that the higher seroprevalence of pH1N1 infection in urban areas may be related to more frequent social contacts and greater density of population. Our finding of increased pH1N1 seroprevalence in school-aged children is consistent with recent serological studies in other countries, as well as a study conducted in Beijing, China [7], [9], [10], [12], [13]. In our study, school-aged children had higher odds of antibody response to pH1N1 infection compared with children in family care. The observed higher odds of seropositivity may be the result of intense social mixing patterns in schools and kindergartens possibly contributing to transmission.
As of January 20, 2010, approximately 65.6 million people had received pH1N1 vaccine in mainland China [26], which accounted for 5% of the population. In contrast, our study found that 9.7% of the population received the pH1N1 vaccine. One possible explanation for the difference may be that individuals who reported receiving the vaccine may have been more willing to participate in the study or that participants misreported receiving any vaccine. The observed antibody response among study subjects who reported receiving the vaccine was lower (62%) than the antibody positive rate from a clinical study in China. This study reported that 74.5–97.3% of the subjects receiving 15 μg of nonadjuvanted vaccine achieved a HI titer ≥40 by day 21[23], [24]. The percentage of individuals reaching seropositivity in this study was also higher than another study conducted in Beijing between late-November and early-December, 2009, where 14.0% of participants reached seropositivity [12]. Our findings showed the subjects reported receiving vaccine still obtained higher seroprevalence than the general population, who presumably experienced natural infection. One possible reason for the lower seroprevalence among the vaccinated population in our study population was that the interval of time between vaccination date and sample collection which was less than 2 weeks and may not have been enough time to develop antibody response. Another possible reason could be recall bias with self-reported vaccination history or misclassification of vaccine in some individuals may report receiving pH1N1 vaccine, but may have received a different vaccine.
The Chinese population had low pre-existing immunity to pH1N1, but experienced a relatively high attack rate in 2009 of this virus. Our finding of high seroprevalence of pandemic influenza H1N1 (2009) (21.5%) after the first peak in autumn-winter season of 2009–2010 in mainland China may explained further by the theory that sustainable transmission is not likely when a significant change in viral antigens is not acquired. Our study findings help to enhance the understanding of the 2009 pH1N1 virus and provide valuable information for the Chinese authorities to develop a vaccination strategy for the coming influenza season.
Baseline serological survey
To assess the baseline prevalence of cross-reactive antibody response to 2009 pandemic H1N1, we used 2,379 stored serum samples collected between 2006 and 2008. These samples were collected from five provinces from different regions of mainland China (Guangdong, Hubei, Shandong, Xinjiang, Yunnan, Figure S2) and were divided into 5 age groups (0–5 years, 6–15 years, 16–24 years, 25–59 years, ≥60 years). Sample sizes for the five age groups ranged from 360 to 556 and more than half (51.1%) were male.
Random-sampling cross-sectional seroprevalence study
Study design
In January 2010, a cross-sectional seroprevelance study to estimate the seroprevalence of 2009 pH1N1 virus infection was approved by the Ministry of Health (MoH) as an emergency study for pandemic response. To select subjects, we utilized a multi-stage stratified random sampling method.
Sampling Method
There are 31 administrative divisions of mainland China (22 provinces, 4 municipalities, 5 autonomous regions) that were divided into eastern, central and western regions by the National Bureau of Statistics of China. For this study, 12 provinces were randomly selected to participate. Four provinces (Beijing, Shandong, Shanghai and Guangdong) were randomly selected from eastern region, four provinces (Henan, Jilin, Anhui and Hunan) from central region, and four provinces (Shaanxi, Xinjiang, Guizhou and Tibet) from western region (Figure 1). Eleven of the twelve selected provinces agreed to conduct the study; Tibet declined to participate. The catchment population in the 11 provinces is 557.1 million, accounting for approximately 43% of the total population in mainland China. The remainder of the multi-stage random sampling method was carried out by each province. Each province was divided into three population strata, a) the core area of the capital city (municipality), b) prefectures of other urban areas and c) prefectures of rural areas. The provinces were then instructed to randomly select at least two districts in each of the three population strata, then 1–2 neighborhoods in each district and finally 1–2 communities/villages in each neighborhood (Figure 2). Once the communities were selected, sampling age groups for subjects 0–5 years, 6–15 years, 16–24 years, 25–59 years and ≥60 years were selected. Before the recruitment of participants, the team responsible for the site survey obtained a name list of all individuals (including age) residing in the communities/villages, and randomly selected individuals from each of age group. With the aid of community/village staff, the selected study subjects were approached and asked if they would like to participate in the study. Overall for each province, 300 persons from each age group in each of the three population strata was the target to enroll in the study. Selected subjects provided informed consent and could decline participation. If a selected individual declined to participate, the next individual on the list was contacted and asked to participate. If the informed consent was obtained from the study participant, the survey questionnaire was completed by a trained interviewer and blood samples were collected. For adults (≥18 years), the informed consent was provided by themselves. For adolescents (10–17 years), the assent was provided by themselves and the informed consent was provided by a parent or a legal guardian of the adolescent. For children (<10 years), the informed consent was provided by a parent or a legal guardian.
Figure 1
Figure 1
11 provinces selected randomly from eastern, central and western regions in the serological cross-sectional survey in January 2010.
Figure 2
Figure 2
The sampling procedures in the serological cross-sectional survey in January 2010.
Sample Size
We expected the seroprevalence to be an estimated 25% and for a 95% confidence interval of +/− 10% (15–35%) we estimated the sample size of 300 from each age group in each of the three strata in each province for an expected sample size from each province of 4,500 and a total of 49,500 subjects.
Investigation and specimen collection
From January 6–29, 2010, a standard questionnaire was administered by trained staff to subjects or guardians if the child was ≤15 years of age. Information collected on the survey included demographics (age, gender, occupation, etc.) and history of a cold, defined as any upper respiratory illness, since May 1, 2009, and pH1N1 vaccination history. The question describing occupation was asked of all individuals regardless of age and was classified as children in family care, children in kindergarten, student, teacher, doctor, and other. Children in family care are defined as the persons aged ≤15 years that do not fit into other categories such as children in kindergarten, students, or did not work in any other organizations or units described in the question. Blood samples were collected from each subject, 5 ml for subjects 6 years or older and 2–3 ml for children younger than 6 years. Serum samples were separated at prefectural Centers for Disease Control and Prevention (CDC) laboratories and then transported to the provincial CDC. After the conclusion of the study, the provincial CDC sent serum samples stored at -30°C and the survey database to the Chinese National Influenza Center (CNIC) of the National Institute for Viral Disease Control and Prevention (IVDC) at China CDC in Beijing for laboratory testing and data analysis.
Laboratory testing
The haemagglutination-inhibition (HI) assay using 0.5% turkey red blood cells was used to test serum for antibody to pH1N1 according to standard protocols [27], [28]. The 2009 pH1N1 antigen used was the A/California/07/2009 virus (provided by U.S. CDC), which was propagated in specific pathogen-free (SPF) embryonated chicken eggs and inactivated with 1‰ paraformaldehyde. A positive serum control (SPF Chicken anti-serum against A/California/07/2009) and negative serum control (sera from health populations before the outbreak of pandemic H1N1) were included in each 96-well plate during the experiment. Prior to testing by the HI assay, serum samples were treated with a 1[ratio]5 (vol/vol) of receptor destroying enzyme (RDE, prepared by CNIC) at 37°C for 18 hours followed by incubation at 56°C for 30 minutes. Serum samples were titrated in 2-fold dilutions in phosphate-buffered saline and tested at an initial dilution of 1[ratio]10. Most individuals infected with influenza develop antibody titers ≥40 by viral HI assay after recovery [7] and was therefore used as marker for immunity against pH1N1 in this study.
Laboratory Quality Control
National specialist groups were convened to guide statistical design, epidemiological investigation, laboratory testing, training and data analysis. Site supervisions by CDC at national or provincial level were conducted during the site investigation. All the villages were selected at the provincial level. Trained County CDC staffs were responsible for administering the questionnaire, collecting the blood specimens, and separating, storing and transporting the serum specimens. Bar code, material for sera collection and separation were provided by CNIC. Five-percent of serum samples were randomly selected from all samples were tested to assess the within-laboratory reproducibility. No more than 18% of replicate tests differed by more than 2-fold. The average reproducibility for positive and negative value is 92%.
Statistical analysis
CNIC issued a standard database to all study sites, which was created in EPI Data software (version 3.02). The survey questionnaires were double inputted into the database and checked for consistency within the provinces. Data were analyzed at CNIC, with SAS 9.1 (SAS Institute, Cary, NC, U.S.) software.
Applying weights to the data
Appropriate sampling weights were constructed for the national database and applied to seroprevalence data to account for the complex sampling design [29][31] and to adjust for age and community setting (capital, urban, rural) which were not representatively sampled. The weight components computed for these data were based on previously published weighting methodology which consisted of base weights and adjustment weights [29][31]. A base weight denotes the probability of selecting a participant from the total number of the sampling units of each sampling stage. Then adjustment weights were calculated to adjust seroprevalence of pH1N1 for differences between census characteristics of study sample and characteristics of the chinese population. The base weight of each sampling stage was calculated by dividing the total number of the sampling unit (e.g. province, capital city, district, neighborhood, village/community, and individual r) by the number of each sampling unit selected, described in Table S1. For example, the base weight for Guangdong Province on the first sampling stage was calculated by dividing the total number of eastern provinces (9) by the number of eastern provinces selected (4). The total base weight for a person (i) was then calculated by multiplying each of the base weights for each selected sampling unit including the person i on each sampling stage. Next the adjusted weights were calculated accounting for gender (male, female), age group (0–5 years, 6–15 years, 16–24 years, 25–59 years, and ≥60 years) and community type (capital city, urban area, or rural area). The adjusted weight of person i was calculated based on the combination of the three strata (age group, gender, and community type) that person i fit into by dividing the actual Chinese population for the combination by the sum of the base weights of all sampled individuals for the same combination of the strata that person i fell into, described in Table S2. The sampling weight of each selected individual was calculated by multiplying the total base weight by the adjustment weight.
To examine the association between risk factors and having a serological response to pH1N1 infection, we conducted multivariable logistic regression analyses. The dependent variable was presence of pH1N1 seropositivity vs. no seropositivity. Independent variables examined were gender, occupation, location of communities (capital city or rural areas vs. other urban areas), region (eastern or central vs. western). The final model examining risk factors for pH1N1 infection included gender, occupation, region, and location of communities (capital city or rural vs. other urban areas). Age group was excluded from the model because of the collinear relationship with occupation (p<0.0001). The surveyfreq procedure in the SAS software package was used to calculate the point estimates and 95% confidence intervals of weighted prevalence and the surveylogistic procedure was used for multivariable logistic regression to examine odds of infection for risk factors [32].
Figure S1
Number of laboratory-confirmed pH1N1 cases and time when the serological cross-sectional survey conducted.
Figure S2
Geographical distribution of stored serum samples collected between 2006 and 2008.
Table S1
The calculation of base weights in each of 6 random sampling stage. The base weight for person i can be expressed as follows: Wbasei = W1 ×W2×W3×W4×W5×W6
Table S2
The calculation of adjustment weights. Adjustment weights (Wadj) were constructed based on post-stratification adjustments to account for the region, sex and age distribution of the entire Chinese population. If person i is located in the cell (row r, column c), his/her adjustment weight can be expressed as follows:
A mathematical equation, expression, or formula.
 Object name is pone.0017919.e001.jpg
Nrc refers to the actual size of the Chinese population in the cell (row r, column c); nrc refers to the sample size in the cell (row r, column c); An external file that holds a picture, illustration, etc.
Object name is pone.0017919.e002.jpg refers to the sum of base weights of all study individuals in the cell (row r, column c).
We thank the 11 local Centers for Disease Control and Prevention of Beijing, Shanghai, Shandong, Henan, Guangdong, Guizhou, Anhui, Hunan, Shaanxi, Xinjiang and Jilin for sample collection and field investigation. We thank Dr. Lee Chin Kei, epidemiologist of Communicable Disease Surveillance Response, WHO China and Dr. Terry Lee, epidemiologist of USCDC/China for their critical reading of the manuscript.We thank Prof. Guo Jing of Renmin University of China for her contribution on study design and data analysis.
Competing Interests: The authors have declared that no competing interests exist.
Funding: This study was mainly supported by the financial allocation of the central government and partly supported by NIH/NIAID Grant 5-U54-AI-057157-08 (Epidemiology and Molecular Mechanism of Highly Pathogenic Avian Influenza H5N1 and Pandemic Influenza H1N1). None of the sponsors participated in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
1. World now at the start of 2009 influenza pandemic. Accessed March 27, 2010.
2. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605–15. [PubMed]
3. 2010. Centers for Disease Control and Prevention. CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States. Accessed March 27, 2010.
4. Health Protection Agency. 2009. Pandemic (H1N1) 2009 influenza: surveillance methodology. Accessed November 25,2009.
5. Turbelin C, Pelat C, Boëlle PY, Lévy-Bruhl D, Carrat F, et al. Early estimates of 2009 pandemic influenza A(H1N1) virus activity in general practice in France: incidence of influenza-like illness and age distribution of reported cases. Euro Surveill; 2009;19341 14: pii. [PubMed]
6. Reed C, Katz M J. Serological surveys for 2009 pandemic influenza A H1N1. The Lancet. 2010;375:1062–1063. [PubMed]
7. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. The Lancet. 2010;375:1100–1108. [PubMed]
8. Chen MI, Lee VJ, Lim WY, Barr IG, Lin RT, et al. 2009 Influenza A(H1N1) Seroconversion Rates and Risk Factors Among Distinct Adult Cohorts in Singapore. JAMA. 2010;303(14):1383–91. [PubMed]
9. Allwinn R, Geiler J, Berger A, Cinatl J, Doerr HW. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Medical Microbiology Immunology. 2010;199:117–121. [PubMed]
10. Ross T, Zimmer S, Burke D, Crevar C, Carter D, et al. Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza. PLoS Curr: Influenza Feb. 2010;24:RRN1148. [PMC free article] [PubMed]
11. Chan Y, Lee CL, Hwang SJ, Fung CP, Wang FD, et al. Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan. Journal of the Chinese Medicine Association. 2010;73:62–66. [PubMed]
12. Deng Y, PANG XH, YANG P, Shi WX, Tian LL. Serological survey of 2009 H1N1 influenza in residents of Beijing, China. Epidemiol. Infect. doi: 10.1017/S0950268810002189. [PubMed]
13. Wu JT, Ma ESK, Lee CK, Chu DK, Ho PL, et al. The Infection Attack Rate and Severity of 2009 Pandemic H1N1 Influenza in Hong Kong. Clinical Infectious Diseases. 2010;51(10):1184–1191. [PMC free article] [PubMed]
14. Cowling BJ, Chan KH, Fang VJ, Lau LL, So HC, et al. Comparative Epidemiology of Pandemic and Seasonal Influenza A in Households. N Engl J Med. 2010;362:2175–2184. [PubMed]
15. Presanis AM, De Angelis D, Hagy A, Reed C, Riley S, et al. The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. Plos medicine. 2009;6(12):e1000207. [PMC free article] [PubMed]
16. Bin C, Xingwang L, Yuelong S, Nan J, Shijun C, et al. Clinical and epidemiologic characteristics of 3 early cases of influenza A pandemic (H1N1) 2009 virus infection, People's Republic of China, 2009. Emerg Infect Dis. 2009;15(9):1418–22. [PMC free article] [PubMed]
17. Chinese National Influenza Center. Chinese Influenza Weekly Report, Week 4: Jan 25- Jan 31. Accessed April 23,2009.
18. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–52. [PubMed]
19. Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Eurosurveillance, 15(5):pii=19478 . 2010. (also available from: [PubMed]
20. Tang JW, Tambyah PA, Wilder-Smith A, Puong KY, Shaw R, et al. Cross–reactive antibodies to pandemic (H1N1) 2009 virus, Singapore. Emerging Infectious Diseases. 2010;16:874–876. [PMC free article] [PubMed]
21. Chen H, Wang Y, Liu W, Zhang J, Dong B, et al. Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis. 2009;15:1849–50. [PMC free article] [PubMed]
22. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460:1021–25. [PMC free article] [PubMed]
23. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009;361:2414–23. [PubMed]
24. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind,randomised, placebo-controlled trial. Lancet Jan 2; 2010;375:56. [PubMed]
25. National Bureau of Statistics People’s Republic of China. 2010. Chinese Statistical Yearly Report in 2010. Beijing, Chinese Statistical Express.
26. Ministry of Health of People's Republic of China. Briefing reports on pandemic (H1N1) 2009 influenza vaccination in China. Accessed April 23,2010.
27. Kendal AP, Skehel JJ, Pereira MS. World Health Organization Collaborating Centers from Reference and Research on Influenza: concepts and procedures for laboratory-based influenza surveillance, 1982;pB17-35
28. WHO, . WHO Manual on animal influenza diagnosis and surveillance. WHO/CDS/CSR/NCS/2002.5. Accessed April 21,2009.
29. Liu J, Jin S. Estimation of Population Quantities and their Variances in Complex Sample Survey. 2008;24(4):377–9. Chinese.
30. Korn E, Graubard B. Examples of differing weighted and unweighted estimates from a sample survey. Am Stat. 1995;49:291.
31. Lohr SL. Sampling: design and analysis. 2002. Beijing, Chinese Statistical Express.
32. SAS Institute Inc. SAS/ STAT 9. 1 User’s Guide. Cary, NC:SAS Institute Inc. 2004 Page 424124250.
Articles from PLoS ONE are provided here courtesy of
Public Library of Science